Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA
Status:
Active, not recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a single-arm, multi-center, open-label, phase II trial to examine the efficacy of
pembrolizumab for prolonging the one-year disease free survival in nasopharyngeal carcinoma
patients with solely detectable EBV DNA after curative chemoradiation. Sixty-three patients
will be enrolled in the trial.
Phase:
Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital Changhua Christian Hospital China Medical University Hospital Koo Foundation Sun Yat-Sen Cancer Center National Cheng-Kung University Hospital National Taiwan University Hospital Taichung Veterans General Hospital